CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna"), announced today
the commencement of a proposed underwritten public offering of 2,750,000
shares of common stock. Dicerna also intends to grant the underwriters a
30-day option to purchase up to an additional 412,500 shares of common
stock. The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.
Dicerna intends to use the net proceeds from the offering for
preclinical studies and clinical trials, with the remainder of any net
proceeds from sales of securities being used for continued technology
platform development, working capital and general corporate purposes.
Jefferies LLC, Leerink Partners LLC and Cowen and Company, LLC are
acting as the joint book-running managers for the offering. Stifel,
Nicolaus & Company, Incorporated is acting as a lead manager for the
offering. When available, copies of the preliminary prospectus
supplement, prospectus supplement, and accompanying base prospectus
relating to the offering may be obtained free of charge on the
Securities and Exchange Commission's website at www.sec.gov.
A shelf registration statement relating to the sale of these securities
has been filed with the Securities and Exchange Commission and has
become effective. A preliminary prospectus supplement relating to the
offering has been filed with the Securities and Exchange Commission.
Copies of the preliminary prospectus supplement and accompanying
prospectus may be obtained by contacting: Jefferies LLC by mail at
Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,
2nd Floor, New York, NY, 10022 or by telephone at 877-547-6340, or by
email at Prospectus_Department@Jefferies.com,
or Leerink Partners LLC by mail at Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800)
808-7525 ext. 6142, or by email at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale
would be unlawful.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the discovery and development of innovative treatments for rare,
inherited diseases involving the liver and for cancers that are
genetically defined. The company is using its proprietary RNA
interference technology platform to build a broad pipeline in these
therapeutic areas. In both rare diseases and oncology, Dicerna is
pursuing targets that have been difficult to address using conventional
approaches, but where connections between targets and diseases are well
understood and documented. The company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Examples of forward-looking statements in
this release include Dicerna's expectations regarding the offering,
including the actual size or terms of the offering, the size of the
underwriter's option to purchase additional shares of common stock,
whether or when the offering may be completed and its anticipated use of
proceeds from the offering. Applicable risks and uncertainties include
those relating to the offering and other risks identified under the
heading "Risk Factors" included in our most recent Form 10-Q filing and
in other future filings with the SEC. The forward-looking statements
contained in this press release reflect Dicerna's current views with
respect to future events, and Dicerna does not undertake and
specifically disclaims any obligation to update any forward-looking
View source version on businesswire.com: http://www.businesswire.com/news/home/20150518006684/en/
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media